Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of BAY 80-6946 + BAY 86-9766 in advanced cancer
NL-OMON39510Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of copanlisib and refametinib in Nonhematologic neoplasms and cancer (2 arms), sponsored by Bayer. Primary endpoints: Safety and tolerability, Recommended phase II dose and 4 more. Started Feb 2012; status: active, not recruiting.
02
Drugs
copanlisibrefametinib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON39510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39510.